// ============================================================
// TERRAIN — Competitor Data: Rare Disease Indications
// lib/data/competitor-data-rare-disease.ts
//
// Competitor records for rare/orphan disease indications.
// Sources: FDA labels, EMA SmPCs, ClinicalTrials.gov,
// company pipelines, peer-reviewed literature (2020-2025)
// ============================================================

import type { CompetitorRecord } from './competitor-database';

export const RARE_DISEASE_COMPETITORS: CompetitorRecord[] = [

  // ══════════════════════════════════════════════════════════
  // GAUCHER DISEASE
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Cerezyme',
    generic_name: 'imiglucerase',
    company: 'Sanofi Genzyme',
    indication: 'Gaucher Disease',
    indication_specifics: 'Type 1 Gaucher disease; long-term ERT for visceral and hematologic manifestations',
    mechanism: 'Recombinant glucocerebrosidase enzyme replacement therapy',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Glucocerebrosidase (GCase)',
    phase: 'Approved',
    primary_endpoint: 'Hemoglobin concentration, platelet count, liver/spleen volume',
    key_data: 'FDA approved 1994; >30 years of real-world data; demonstrated sustained reductions in liver/spleen volumes and normalization of hematologic parameters in pivotal trials',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Gold standard ERT with decades of safety data',
      'Well-characterized long-term outcomes across all age groups',
      'Global availability and extensive physician familiarity',
    ],
    weaknesses: [
      'Requires biweekly IV infusions (1-2 hours)',
      'Very high annual cost (~$300,000+/year)',
      'Does not cross blood-brain barrier; ineffective for neuronopathic forms (Types 2/3)',
    ],
    source: 'FDA label; Sanofi Genzyme prescribing information; Grabowski et al., Mol Genet Metab 2016',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Cerdelga',
    generic_name: 'eliglustat',
    company: 'Sanofi Genzyme',
    indication: 'Gaucher Disease',
    indication_specifics: 'Type 1 Gaucher disease in adults who are CYP2D6 extensive, intermediate, or poor metabolizers',
    mechanism: 'Glucosylceramide synthase inhibitor (substrate reduction therapy)',
    mechanism_category: 'substrate_reduction_therapy',
    molecular_target: 'Glucosylceramide synthase (UDP-glucose ceramide glucosyltransferase)',
    phase: 'Approved',
    primary_endpoint: 'Composite endpoint: hemoglobin, platelet count, spleen volume, liver volume',
    key_data: 'FDA approved 2014; ENGAGE (treatment-naive) and ENCORE (switch from ERT) Phase 3 trials showed non-inferiority to Cerezyme on composite endpoint; 4-year extension data confirmed durability',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First oral therapy for Gaucher disease; eliminates need for IV infusions',
      'Non-inferior to Cerezyme in both treatment-naive and ERT-switch patients',
      'Favorable safety profile with long-term extension data',
    ],
    weaknesses: [
      'Requires CYP2D6 genotyping prior to prescribing (excluded ~5-10% ultra-rapid metabolizers)',
      'Significant drug-drug interactions with CYP2D6 and CYP3A inhibitors',
      'Not approved for neuronopathic Gaucher disease',
    ],
    source: 'FDA label; ENGAGE trial (NCT00891202); ENCORE trial (NCT00943111); Mistry et al., JAMA 2015',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Vpriv',
    generic_name: 'velaglucerase alfa',
    company: 'Takeda (Shire)',
    indication: 'Gaucher Disease',
    indication_specifics: 'Type 1 Gaucher disease; ERT for pediatric and adult patients',
    mechanism: 'Gene-activated recombinant glucocerebrosidase enzyme replacement therapy',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Glucocerebrosidase (GCase)',
    phase: 'Approved',
    primary_endpoint: 'Hemoglobin concentration change from baseline',
    key_data: 'FDA approved 2010; Phase 3 (TKT034) demonstrated clinically meaningful improvements in hemoglobin (+2.4 g/dL), platelet counts, and organ volumes; human cell-line derived (no risk of prion contamination)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Produced in human cell line (HT-1080 fibrosarcoma) with native human glycosylation pattern',
      'Lower immunogenicity profile vs. CHO-cell derived ERTs',
      'Demonstrated efficacy in treatment-naive and ERT-switch patients',
    ],
    weaknesses: [
      'Requires biweekly IV infusions similar to Cerezyme',
      'Smaller market share and less long-term data vs. Cerezyme',
      'Does not address neuronopathic disease',
    ],
    source: 'FDA label; TKT034 trial; Zimran et al., Blood 2011',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // POMPE DISEASE
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Lumizyme',
    generic_name: 'alglucosidase alfa',
    company: 'Sanofi Genzyme',
    indication: 'Pompe Disease',
    indication_specifics: 'Infantile-onset and late-onset Pompe disease (glycogen storage disease type II)',
    mechanism: 'Recombinant acid alpha-glucosidase enzyme replacement therapy',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Acid alpha-glucosidase (GAA)',
    phase: 'Approved',
    primary_endpoint: 'Invasive ventilator-free survival (infantile); 6-minute walk test, FVC (late-onset)',
    key_data: 'FDA approved 2006 (Myozyme) / 2010 (Lumizyme); LOTS trial in late-onset showed stabilization of walking distance (+25.1m vs -13.6m placebo) and respiratory function over 78 weeks',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First and longest-standing approved ERT for Pompe disease',
      'Demonstrated survival benefit in infantile-onset disease',
      'Extensive real-world evidence across age groups and phenotypes',
    ],
    weaknesses: [
      'Suboptimal muscle uptake due to mannose-6-phosphate receptor saturation',
      'Infusion-associated reactions common; requires pre-medication',
      'Decline in efficacy over time due to antibody development in some patients',
    ],
    source: 'FDA label; LOTS trial (NCT00158600); van der Ploeg et al., NEJM 2010',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Nexviazyme',
    generic_name: 'avalglucosidase alfa',
    company: 'Sanofi Genzyme',
    indication: 'Pompe Disease',
    indication_specifics: 'Late-onset Pompe disease in patients 1 year and older',
    mechanism: 'Bis-phosphorylated recombinant acid alpha-glucosidase with enhanced M6P receptor targeting',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Acid alpha-glucosidase (GAA) via cation-independent mannose-6-phosphate receptor',
    phase: 'Approved',
    primary_endpoint: '6-minute walk test distance, forced vital capacity (FVC)',
    key_data: 'FDA approved 2021; COMET trial (Phase 3) in ERT-naive LOPD: statistically significant superiority over alglucosidase alfa in respiratory function (FVC% predicted +2.89% difference, p=0.023) with trend toward improved walking distance',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Enhanced M6P content enables 15x higher receptor binding and improved muscle uptake',
      'Demonstrated superiority over Lumizyme in respiratory endpoints',
      'Positioned as next-generation standard of care for Pompe disease',
    ],
    weaknesses: [
      'Still requires biweekly IV infusions',
      'Limited long-term data compared to Lumizyme',
      'Premium pricing over Lumizyme limits uptake in cost-sensitive markets',
    ],
    source: 'FDA label; COMET trial (NCT02782741); Diaz-Manera et al., Lancet Neurol 2021',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Pombiliti',
    generic_name: 'cipaglucosidase alfa',
    company: 'Amicus Therapeutics',
    indication: 'Pompe Disease',
    indication_specifics: 'Late-onset Pompe disease; administered with miglustat (AT-GAA combination)',
    mechanism: 'Recombinant acid alpha-glucosidase co-administered with miglustat as enzyme stabilizer',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Acid alpha-glucosidase (GAA) stabilized by miglustat chaperone',
    phase: 'Approved',
    primary_endpoint: '6-minute walk test distance, forced vital capacity (FVC)',
    key_data: 'FDA approved 2023; PROPEL Phase 3 trial: combination of cipaglucosidase alfa + miglustat showed improvements in 6MWT (+20.8m vs +7.2m alglucosidase alfa) and FVC in ERT-experienced LOPD patients; FDA label includes both ERT-naive and switch',
    line_of_therapy: '1L',
    partner: 'WKS (co-administration with miglustat chaperone)',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Chaperone-enzyme combination improves enzyme stability and muscle delivery',
      'Demonstrated improvements in both walking distance and respiratory function vs. standard ERT',
      'Novel stabilization approach may reduce immunogenicity',
    ],
    weaknesses: [
      'Requires two-component regimen (IV infusion + oral miglustat)',
      'Complex dosing schedule and administration protocol',
      'Limited head-to-head data against Nexviazyme',
    ],
    source: 'FDA label; PROPEL trial (NCT03729362); Schoser et al., Lancet Neurol 2023',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // FABRY DISEASE
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Fabrazyme',
    generic_name: 'agalsidase beta',
    company: 'Sanofi Genzyme',
    indication: 'Fabry Disease',
    indication_specifics: 'Fabry disease (alpha-galactosidase A deficiency) in pediatric and adult patients',
    mechanism: 'Recombinant alpha-galactosidase A enzyme replacement therapy',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Alpha-galactosidase A (GLA)',
    phase: 'Approved',
    primary_endpoint: 'GL-3 clearance from kidney, cardiac, and skin endothelium',
    key_data: 'FDA approved 2003; Phase 3 trial demonstrated significant GL-3 clearance from capillary endothelium of kidney (69% vs 0% placebo, p<0.001); 10-year follow-up showed stabilization of renal function and cardiac outcomes in early-treated patients',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First approved ERT for Fabry disease with 20+ years of clinical experience',
      'Demonstrated histological GL-3 clearance across multiple organ systems',
      'Strong long-term data supporting renal and cardiac benefit when started early',
    ],
    weaknesses: [
      'Biweekly IV infusions (~3-4 hours); significant patient burden',
      'Infusion-associated reactions and antibody development in many male patients',
      'Annual cost exceeds $300,000; supply disruptions historically problematic',
    ],
    source: 'FDA label; Eng et al., NEJM 2001; Germain et al., J Med Genet 2015',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Galafold',
    generic_name: 'migalastat',
    company: 'Amicus Therapeutics',
    indication: 'Fabry Disease',
    indication_specifics: 'Fabry disease in adults with amenable GLA variants (pharmacological chaperone)',
    mechanism: 'Pharmacological chaperone that stabilizes amenable mutant forms of alpha-galactosidase A',
    mechanism_category: 'pharmacological_chaperone',
    molecular_target: 'Alpha-galactosidase A (GLA) — amenable variants only',
    phase: 'Approved',
    primary_endpoint: 'GL-3 inclusions in kidney interstitial capillaries; eGFR stability',
    key_data: 'FDA approved 2018; ATTRACT trial showed non-inferior renal function preservation vs. ERT over 18 months in amenable patients; FACETS trial showed significant GL-3 reduction from baseline in amenable patients (-0.25 vs +0.07, p=0.008)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Only oral therapy for Fabry disease; every-other-day capsule eliminates infusion burden',
      'Well-tolerated with favorable safety profile',
      'Amenability assay provides precision medicine approach',
    ],
    weaknesses: [
      'Only effective in patients with amenable GLA variants (~35-50% of known variants)',
      'Not indicated for non-amenable (classic) Fabry disease mutations',
      'Limited long-term outcome data compared to decades of ERT experience',
    ],
    source: 'FDA label; ATTRACT trial (NCT01218659); FACETS trial (NCT00925301); Hughes et al., J Med Genet 2017',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Elfabrio',
    generic_name: 'pegunigalsidase alfa',
    company: 'Chiesi Global Rare Diseases (Protalix BioTherapeutics)',
    indication: 'Fabry Disease',
    indication_specifics: 'Fabry disease in adults; PEGylated plant cell-derived ERT',
    mechanism: 'PEGylated recombinant alpha-galactosidase A with extended half-life',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Alpha-galactosidase A (GLA)',
    phase: 'Approved',
    primary_endpoint: 'eGFR annualized rate of change; GL-3 substrate reduction',
    key_data: 'FDA approved 2023; BRIDGE Phase 3 trial demonstrated non-inferiority to agalsidase beta on eGFR slope over 24 months in ERT-switch patients; BRIGHT Phase 3 showed stable eGFR in treatment-naive patients; PEGylation extends half-life enabling every-4-week dosing',
    line_of_therapy: '1L',
    partner: 'Protalix BioTherapeutics (co-development)',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'PEGylation extends half-life, allowing less frequent dosing (every 4 weeks vs. biweekly)',
      'Plant cell-derived production may reduce immunogenicity risk',
      'Non-inferior to agalsidase beta in renal outcome measures',
    ],
    weaknesses: [
      'Still requires IV infusion administration',
      'Late market entrant competing against established ERT and oral chaperone',
      'Limited long-term safety data on PEGylated enzyme therapy',
    ],
    source: 'FDA label; BRIDGE trial (NCT03180840); BRIGHT trial (NCT02795676); Schiffmann et al., Mol Genet Metab 2023',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // HEREDITARY ANGIOEDEMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Takhzyro',
    generic_name: 'lanadelumab',
    company: 'Takeda',
    indication: 'Hereditary Angioedema',
    indication_specifics: 'Prevention of HAE attacks in patients aged 12+ with C1-inhibitor deficiency (Types I and II)',
    mechanism: 'Fully human monoclonal antibody inhibiting plasma kallikrein',
    mechanism_category: 'monoclonal_antibody',
    molecular_target: 'Plasma kallikrein',
    phase: 'Approved',
    primary_endpoint: 'Number of investigator-confirmed HAE attacks per month',
    key_data: 'FDA approved 2018; HELP trial (Phase 3): 87% reduction in HAE attack rate vs. placebo (0.26 vs. 1.97 attacks/month, p<0.001); 44% of patients achieved zero attacks over treatment period; every-2-week SC dosing',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Best-in-class attack rate reduction (87%) with substantial zero-attack rates',
      'Convenient self-administered SC injection every 2 weeks (or monthly for well-controlled patients)',
      'Durable efficacy maintained in long-term extension studies',
    ],
    weaknesses: [
      'Injection site reactions common (>40%)',
      'Annual cost ~$400,000-500,000; payer pushback on long-term prophylaxis',
      'Only indicated for prophylaxis; not for acute attack treatment',
    ],
    source: 'FDA label; HELP trial (NCT02586805); Banerji et al., JAMA 2018',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Orladeyo',
    generic_name: 'berotralstat',
    company: 'BioCryst Pharmaceuticals',
    indication: 'Hereditary Angioedema',
    indication_specifics: 'Prophylaxis to prevent HAE attacks in adults and pediatric patients aged 12+',
    mechanism: 'Oral plasma kallikrein inhibitor',
    mechanism_category: 'small_molecule_inhibitor',
    molecular_target: 'Plasma kallikrein',
    phase: 'Approved',
    primary_endpoint: 'Rate of investigator-confirmed HAE attacks per 28-day period',
    key_data: 'FDA approved 2020; APeX-2 Phase 3 trial: 150mg dose reduced HAE attack rate by 44% vs. placebo (1.31 vs. 2.35 attacks/28 days, p=0.003); first and only oral prophylactic for HAE',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Only oral once-daily prophylactic therapy for HAE; no injections required',
      'Ease of administration improves patient adherence and quality of life',
      'Favorable safety profile with low discontinuation rates',
    ],
    weaknesses: [
      'Lower attack rate reduction (44%) vs. Takhzyro (87%)',
      'GI side effects (abdominal pain, vomiting, diarrhea) common',
      'Moderate efficacy may position as second-line behind Takhzyro in severe patients',
    ],
    source: 'FDA label; APeX-2 trial (NCT03485573); Zuraw et al., NEJM 2021',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Haegarda',
    generic_name: 'C1 esterase inhibitor subcutaneous (human)',
    company: 'CSL Behring',
    indication: 'Hereditary Angioedema',
    indication_specifics: 'Routine prophylaxis against HAE attacks in adolescents and adults',
    mechanism: 'Plasma-derived C1 esterase inhibitor (C1-INH) replacement therapy, subcutaneous formulation',
    mechanism_category: 'protein_replacement_therapy',
    molecular_target: 'C1 esterase inhibitor (C1-INH)',
    phase: 'Approved',
    primary_endpoint: 'Number of HAE attacks; time-normalized number of HAE attacks',
    key_data: 'FDA approved 2017; COMPACT Phase 3 trial: 60 IU/kg twice-weekly SC dosing reduced HAE attack rate by 95% vs. placebo (median 0 attacks vs. 4.0 attacks/month); 40% of subjects were attack-free during treatment',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Plasma-derived physiologic replacement; well-understood mechanism of action',
      'Subcutaneous self-administration; no need for IV access',
      'Very high attack rate reduction (95% in COMPACT) with good tolerability',
    ],
    weaknesses: [
      'Twice-weekly injections required; higher administration frequency than Takhzyro',
      'Plasma-derived product with theoretical pathogen transmission risk',
      'Large injection volume; injection site reactions',
    ],
    source: 'FDA label; COMPACT trial (NCT01912456); Longhurst et al., NEJM 2017',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // PHENYLKETONURIA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Palynziq',
    generic_name: 'pegvaliase',
    company: 'BioMarin Pharmaceutical',
    indication: 'Phenylketonuria',
    indication_specifics: 'PKU in adults with uncontrolled blood Phe concentrations >600 micromol/L on existing management',
    mechanism: 'PEGylated recombinant phenylalanine ammonia lyase (PAL) enzyme substitution',
    mechanism_category: 'enzyme_substitution_therapy',
    molecular_target: 'Phenylalanine (substrate reduction via PAL enzyme)',
    phase: 'Approved',
    primary_endpoint: 'Blood phenylalanine (Phe) concentration reduction from baseline',
    key_data: 'FDA approved 2018; PRISM-2 Phase 3: 60.7% mean reduction in blood Phe at 24 months; 36.6% of patients achieved Phe <=120 micromol/L (normal range); REMS program required due to anaphylaxis risk',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Only treatment that can normalize blood Phe levels regardless of PAH genotype',
      'Enables dietary liberalization; transformative for quality of life in severe PKU',
      'Long-term data show sustained Phe control over 4+ years',
    ],
    weaknesses: [
      'REMS program required due to anaphylaxis risk (~5% incidence)',
      'Complex dose titration over months; requires close monitoring during induction',
      'Daily self-injection; injection site reactions very common (>60%)',
    ],
    source: 'FDA label; PRISM-2 trial (NCT01889862); Harding et al., Lancet 2018',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Kuvan',
    generic_name: 'sapropterin dihydrochloride',
    company: 'BioMarin Pharmaceutical',
    indication: 'Phenylketonuria',
    indication_specifics: 'PKU in BH4-responsive patients to reduce blood Phe, used as adjunct to dietary management',
    mechanism: 'Synthetic tetrahydrobiopterin (BH4) cofactor; enhances residual PAH enzyme activity',
    mechanism_category: 'cofactor_therapy',
    molecular_target: 'Phenylalanine hydroxylase (PAH) — residual enzyme activity',
    phase: 'Approved',
    primary_endpoint: 'Blood phenylalanine (Phe) reduction from baseline',
    key_data: 'FDA approved 2007; Phase 3 PKU-003: mean Phe reduction of 236 micromol/L (-30%) vs. placebo in BH4-responsive patients; response rate ~25-50% of PKU population depending on genotype; pediatric approvals expanded reach',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Oral therapy (dissolved tablet); well-tolerated and non-invasive',
      'Allows dietary relaxation in responsive patients',
      'Approved for all ages including infants; long-term safety established',
    ],
    weaknesses: [
      'Only effective in BH4-responsive patients (~25-50% of PKU population)',
      'Requires BH4 responsiveness testing before initiation',
      'Modest Phe reduction (~30%); many patients remain on significant dietary protein restriction',
    ],
    source: 'FDA label; PKU-003 trial (NCT00056264); Levy et al., Lancet 2007',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // WILSON DISEASE
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Cuprimine',
    generic_name: 'penicillamine',
    company: 'Bausch Health (Valeant)',
    indication: 'Wilson Disease',
    indication_specifics: 'Wilson disease copper chelation; removal of excess copper from tissues',
    mechanism: 'Copper chelation agent; binds copper and promotes renal excretion',
    mechanism_category: 'chelation_therapy',
    molecular_target: 'Copper (Cu2+)',
    phase: 'Approved',
    primary_endpoint: '24-hour urinary copper excretion; free serum copper normalization',
    key_data: 'FDA approved 1956; first-line chelator for >60 years; effective decoppering agent with well-documented clinical experience; initial neurological worsening reported in 10-50% of neurologic Wilson disease patients',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Decades of clinical experience; most widely used chelator worldwide',
      'Effective copper removal with documented long-term outcomes',
      'Low cost and wide generic availability',
    ],
    weaknesses: [
      'High rate of adverse effects: bone marrow suppression, nephrotoxicity, lupus-like syndrome',
      'Risk of initial neurological worsening in 10-50% of neurologic presentations',
      'Requires frequent laboratory monitoring; poor tolerability leads to discontinuation in ~30%',
    ],
    source: 'FDA label; EASL Clinical Practice Guidelines, J Hepatol 2012; Weiss & Stremmel, Hepatology 2012',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Syprine',
    generic_name: 'trientine dihydrochloride',
    company: 'Bausch Health (Valeant)',
    indication: 'Wilson Disease',
    indication_specifics: 'Wilson disease in patients intolerant of penicillamine',
    mechanism: 'Copper chelation agent; polyamine chelator that promotes renal copper excretion',
    mechanism_category: 'chelation_therapy',
    molecular_target: 'Copper (Cu2+)',
    phase: 'Approved',
    primary_endpoint: '24-hour urinary copper excretion; free serum copper normalization',
    key_data: 'FDA approved 1985; better tolerated than penicillamine with lower rates of hypersensitivity and bone marrow suppression; generally considered second-line, but increasingly used as first-line given superior tolerability',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Significantly better tolerability profile than penicillamine',
      'Lower risk of neurological worsening on treatment initiation',
      'Effective copper chelation with acceptable safety for long-term use',
    ],
    weaknesses: [
      'Historically positioned as second-line; less prescriber familiarity as initial therapy',
      'Iron deficiency can occur with long-term use',
      'Requires empty stomach dosing (1 hour before or 2 hours after meals); multiple daily doses',
    ],
    source: 'FDA label; Weiss & Stremmel, Hepatology 2012; EASL Guidelines',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Bis-choline tetrathiomolybdate',
    generic_name: 'ALXN1840 (decuprate)',
    company: 'Alexion (AstraZeneca)',
    indication: 'Wilson Disease',
    indication_specifics: 'Wilson disease; novel copper-protein binding agent with dual mechanism',
    mechanism: 'Copper-protein binding agent; forms tripartite complex with copper and albumin, plus intracellular copper chaperone',
    mechanism_category: 'chelation_therapy',
    molecular_target: 'Copper — intracellular and extracellular pools',
    phase: 'Phase 3',
    primary_endpoint: 'Corrected non-ceruloplasmin-bound copper (NCC) normalization',
    key_data: 'FoCus Phase 3 trial: met primary endpoint with 72% of patients achieving NCC normalization at 48 weeks vs. 0% for penicillamine comparator arm; significantly lower rate of neurological worsening (3% vs. 9%)',
    line_of_therapy: '1L',
    nct_ids: ['NCT03403205'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Dual mechanism: extracellular copper-albumin complex formation + intracellular copper depletion',
      'Significantly lower rate of neurological worsening vs. penicillamine',
      'Once-daily oral dosing; simplified administration vs. existing chelators',
    ],
    weaknesses: [
      'Not yet approved; regulatory submission timing uncertain',
      'Hepatic transaminase elevations observed as safety signal',
      'Novel mechanism requires physician education and monitoring protocol development',
    ],
    source: 'FoCus trial (NCT03403205); Weiss et al., Lancet Gastroenterol Hepatol 2022; Alexion pipeline disclosures',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // LYSOSOMAL ACID LIPASE DEFICIENCY
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Kanuma',
    generic_name: 'sebelipase alfa',
    company: 'Alexion (AstraZeneca)',
    indication: 'Lysosomal Acid Lipase Deficiency',
    indication_specifics: 'LAL deficiency (Wolman disease / cholesteryl ester storage disease) in pediatric and adult patients',
    mechanism: 'Recombinant lysosomal acid lipase enzyme replacement therapy',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Lysosomal acid lipase (LAL / LIPA)',
    phase: 'Approved',
    primary_endpoint: 'ALT normalization (ARISE trial); survival to 12 months (infantile trial)',
    key_data: 'FDA approved 2015; ARISE Phase 3 in CESD: 31% achieved ALT normalization vs. 7% placebo (p=0.033); significant LDL-C reduction (-28% vs. -6%); in rapidly progressive infantile Wolman disease, 67% survival to 12 months vs. 0% historical',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Only approved therapy for LAL deficiency; addresses unmet need with no alternatives',
      'Dramatic survival benefit in infantile-onset Wolman disease',
      'Significant improvement in hepatic transaminases and lipid profile in CESD',
    ],
    weaknesses: [
      'Very small patient population (~1 in 40,000-300,000) limits commercial potential',
      'Biweekly IV infusions; anti-drug antibodies develop in some patients',
      'Ultra-orphan pricing (~$300,000+/year) with challenging reimbursement in some markets',
    ],
    source: 'FDA label; ARISE trial (NCT01757184); Burton et al., NEJM 2015',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Supportive care',
    company: 'Standard of care',
    indication: 'Lysosomal Acid Lipase Deficiency',
    indication_specifics: 'Dietary management, statins, and liver transplant as supportive measures for LAL-D prior to or alongside ERT',
    mechanism: 'Lipid-lowering agents (statins), dietary fat restriction, organ transplant for end-stage disease',
    mechanism_category: 'supportive_care',
    phase: 'Approved',
    primary_endpoint: 'LDL-C reduction; hepatic disease stabilization',
    key_data: 'Statins reduce LDL-C but do not address underlying lysosomal storage; liver transplant has been performed in severe CESD but carries significant morbidity/mortality; dietary restriction provides symptomatic relief only',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Widely available and inexpensive',
      'Statins provide partial lipid normalization',
      'Liver transplant can be curative in select end-stage cases',
    ],
    weaknesses: [
      'Does not address underlying enzyme deficiency or lysosomal substrate accumulation',
      'Statins alone insufficient; hepatic disease progression continues',
      'Transplant carries significant surgical risk and lifelong immunosuppression',
    ],
    source: 'Bernstein et al., J Hepatol 2013; Reiner et al., Atherosclerosis 2014',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // ACUTE HEPATIC PORPHYRIA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Givlaari',
    generic_name: 'givosiran',
    company: 'Alnylam Pharmaceuticals',
    indication: 'Acute Hepatic Porphyria',
    indication_specifics: 'AHP in adults; prophylaxis against acute porphyria attacks (AIP, VP, HCP, ADP)',
    mechanism: 'GalNAc-conjugated siRNA targeting ALAS1 mRNA; reduces aminolevulinic acid (ALA) and porphobilinogen (PBG)',
    mechanism_category: 'rna_interference',
    molecular_target: 'ALAS1 (aminolevulinic acid synthase 1) mRNA',
    phase: 'Approved',
    primary_endpoint: 'Annualized rate of porphyria attacks requiring hospitalization, urgent healthcare visit, or IV hemin',
    key_data: 'FDA approved 2019; ENVISION Phase 3: 74% reduction in annualized attack rate vs. placebo (median 1.0 vs. 6.5 attacks, p<0.001); sustained reductions in urinary ALA and PBG; monthly SC injection',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Transformative efficacy: 74% attack rate reduction; many patients achieve zero attacks',
      'Monthly subcutaneous injection; convenient self-administration',
      'First targeted therapy for AHP; addresses root cause by reducing toxic heme precursors',
    ],
    weaknesses: [
      'Hepatotoxicity signal: ALT elevations in ~15% of patients',
      'Renal function decline observed; requires monitoring of eGFR',
      'Annual cost ~$500,000+; very small patient population limits market size',
    ],
    source: 'FDA label; ENVISION trial (NCT03338816); Balwani et al., NEJM 2020',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Panhematin',
    generic_name: 'hemin for injection',
    company: 'Recordati Rare Diseases',
    indication: 'Acute Hepatic Porphyria',
    indication_specifics: 'Treatment of acute porphyria attacks; amelioration of recurrent attacks in AIP, VP, HCP',
    mechanism: 'Exogenous heme replenishment; represses hepatic ALAS1 via negative feedback on heme biosynthesis',
    mechanism_category: 'heme_replacement',
    molecular_target: 'ALAS1 (negative feedback regulation via heme pool replenishment)',
    phase: 'Approved',
    primary_endpoint: 'Resolution of acute attack symptoms; reduction in urinary ALA and PBG',
    key_data: 'FDA approved 1983; standard of care for acute porphyria attacks for 40+ years; rapidly reduces urinary ALA and PBG within 24-48 hours; prevents need for opioids and hospitalization when given early',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Rapid biochemical response within 24-48 hours; effective acute attack treatment',
      'Decades of clinical experience and established place in therapy guidelines',
      'Addresses acute attacks that can be life-threatening if untreated',
    ],
    weaknesses: [
      'IV administration only; requires healthcare facility visit during each attack',
      'Coagulopathy and phlebitis at infusion site; requires large-bore IV or central line',
      'Does not prevent attacks; purely reactive treatment with no prophylactic benefit',
    ],
    source: 'FDA label; Anderson et al., Ann Intern Med 2005; AASLD/ACG porphyria management guidelines',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // HEMOPHILIA B
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Hemgenix',
    generic_name: 'etranacogene dezaparvovec',
    company: 'CSL Behring',
    indication: 'Hemophilia B',
    indication_specifics: 'Moderately severe to severe hemophilia B (Factor IX <=2 IU/dL) in adults with or without factor IX inhibitors',
    mechanism: 'AAV5-based gene therapy delivering functional Padua variant Factor IX transgene',
    mechanism_category: 'gene_therapy',
    molecular_target: 'FIX gene (Factor IX Padua variant, R338L gain-of-function)',
    phase: 'Approved',
    primary_endpoint: 'Annualized bleeding rate (ABR); factor IX activity level',
    key_data: 'FDA approved 2022 (first gene therapy for hemophilia); HOPE-B Phase 3: mean Factor IX activity 39 IU/dL at 18 months (vs. <2 IU/dL baseline); 54% reduction in ABR; 98% of patients discontinued routine prophylaxis; one-time IV infusion priced at $3.5M',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Potentially curative: one-time treatment eliminates lifelong factor replacement',
      'Padua variant transgene produces hyperactive FIX (5-8x higher specific activity)',
      'Sustained FIX activity levels in hemostatic range (>5 IU/dL) through 3+ years',
    ],
    weaknesses: [
      '$3.5M list price; most expensive single drug administration in history',
      'Uncertain durability beyond 3-5 years; potential for transgene expression decline',
      'Excluded patients with pre-existing AAV5 neutralizing antibodies (~30-40%)',
    ],
    source: 'FDA label; HOPE-B trial (NCT03569891); Pipe et al., NEJM 2023',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Alprolix',
    generic_name: 'eftrenonacog alfa',
    company: 'Sanofi (Bioverativ)',
    indication: 'Hemophilia B',
    indication_specifics: 'Routine prophylaxis and on-demand treatment of bleeding in hemophilia B',
    mechanism: 'Fc-fusion recombinant Factor IX with extended half-life',
    mechanism_category: 'factor_replacement',
    molecular_target: 'Factor IX (FIX-Fc fusion)',
    phase: 'Approved',
    primary_endpoint: 'Annualized bleeding rate (ABR)',
    key_data: 'FDA approved 2014; B-LONG Phase 3: weekly prophylaxis achieved median ABR of 1.4; interval prophylaxis (every 10-14 days) achieved median ABR of 2.4; Fc fusion extends half-life to ~82 hours vs. ~34 hours for standard rFIX',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Extended half-life (~2.4x vs. standard rFIX) enables weekly or biweekly dosing',
      'Well-established long-term safety and efficacy profile',
      'Fc domain recycling via neonatal Fc receptor (FcRn) provides predictable pharmacokinetics',
    ],
    weaknesses: [
      'Still requires regular IV injections; not curative',
      'Gene therapy (Hemgenix) increasingly positioned as preferred long-term option',
      'Inhibitor development risk, though low in previously treated patients',
    ],
    source: 'FDA label; B-LONG trial (NCT01027364); Powell et al., NEJM 2013',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'BeneFIX',
    generic_name: 'nonacog alfa',
    company: 'Pfizer',
    indication: 'Hemophilia B',
    indication_specifics: 'Control and prevention of bleeding episodes and perioperative management in hemophilia B',
    mechanism: 'Recombinant Factor IX replacement therapy',
    mechanism_category: 'factor_replacement',
    molecular_target: 'Factor IX (recombinant)',
    phase: 'Approved',
    primary_endpoint: 'Hemostatic efficacy; annualized bleeding rate',
    key_data: 'FDA approved 1997; first recombinant FIX product; pivotal trial demonstrated effective hemostasis in >90% of bleeding episodes; standard half-life (~24 hours) requiring dosing every 2-3 days for prophylaxis',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First recombinant FIX with nearly 30 years of clinical experience',
      'Excellent safety record; no confirmed transmissible disease events',
      'Available in multiple dose strengths; well-characterized PK profile',
    ],
    weaknesses: [
      'Standard half-life requires frequent dosing (2-3x weekly for prophylaxis)',
      'Superseded by extended half-life products (Alprolix, Idelvion, Rebinyn)',
      'Gene therapy availability further diminishes long-term commercial outlook',
    ],
    source: 'FDA label; Pfizer prescribing information; Shapiro et al., Thromb Haemost 2005',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // HUNTER SYNDROME (MPS II)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Elaprase',
    generic_name: 'idursulfase',
    company: 'Takeda (Shire)',
    indication: 'Hunter Syndrome',
    indication_specifics: 'Mucopolysaccharidosis II (Hunter syndrome); systemic ERT for somatic manifestations',
    mechanism: 'Recombinant iduronate-2-sulfatase enzyme replacement therapy',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Iduronate-2-sulfatase (IDS)',
    phase: 'Approved',
    primary_endpoint: 'Composite endpoint: 6-minute walk test + forced vital capacity (%FVC)',
    key_data: 'FDA approved 2006; Phase 2/3 trial: significant improvement in composite endpoint of 6MWT + %FVC (p=0.0049) vs. placebo at 53 weeks; reduced liver and spleen size; reduced urinary GAG levels by ~50%',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Only approved therapy for Hunter syndrome; addresses significant unmet need',
      'Documented improvement in walking capacity, respiratory function, and organomegaly',
      'Long-term safety established over 15+ years of commercial use',
    ],
    weaknesses: [
      'Weekly IV infusions of 1-3 hours; significant patient and caregiver burden',
      'Does not cross blood-brain barrier; no benefit for CNS manifestations',
      'Infusion-associated reactions and anti-drug antibody development common',
    ],
    source: 'FDA label; Muenzer et al., Genet Med 2006; Phase 2/3 (NCT00069641)',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Idursulfase IT',
    generic_name: 'idursulfase intrathecal (investigational)',
    company: 'Takeda (Shire)',
    indication: 'Hunter Syndrome',
    indication_specifics: 'CNS manifestations of Hunter syndrome (neuronopathic MPS II); intrathecal delivery',
    mechanism: 'Intrathecal delivery of recombinant iduronate-2-sulfatase to bypass blood-brain barrier',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Iduronate-2-sulfatase (IDS) — CNS delivery',
    phase: 'Phase 2/3',
    primary_endpoint: 'CSF heparan sulfate and dermatan sulfate levels; neurodevelopmental outcomes (DQ/IQ scores)',
    key_data: 'Phase 2/3 (AIM-IT) evaluated monthly intrathecal idursulfase-IT via implanted intrathecal drug delivery device; demonstrated CSF GAG reduction but mixed neurodevelopmental outcomes; FDA complete response letter issued',
    line_of_therapy: '1L',
    nct_ids: ['NCT02055118'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Directly addresses devastating CNS disease that systemic ERT cannot reach',
      'Demonstrated biochemical proof-of-concept with CSF GAG reduction',
      'No alternative approved therapy for neuronopathic MPS II',
    ],
    weaknesses: [
      'Requires implanted intrathecal drug delivery device; surgical risk',
      'Mixed clinical outcomes in neurodevelopmental endpoints',
      'Received FDA complete response letter; regulatory path uncertain',
    ],
    source: 'AIM-IT trial (NCT02055118); Muenzer et al., Mol Genet Metab 2016; Takeda pipeline disclosures',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // HURLER SYNDROME (MPS I)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Aldurazyme',
    generic_name: 'laronidase',
    company: 'Sanofi Genzyme / BioMarin',
    indication: 'Hurler Syndrome',
    indication_specifics: 'Mucopolysaccharidosis I (MPS I; Hurler, Hurler-Scheie, Scheie syndromes); systemic ERT',
    mechanism: 'Recombinant alpha-L-iduronidase enzyme replacement therapy',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Alpha-L-iduronidase (IDUA)',
    phase: 'Approved',
    primary_endpoint: 'Forced vital capacity (%FVC); 6-minute walk test distance',
    key_data: 'FDA approved 2003; Phase 3 trial: significant improvement in %FVC (+5.6 percentage points vs. placebo, p<0.001) and 6MWT (+38.1m vs. placebo, p=0.039) at 26 weeks; long-term extension showed sustained respiratory and functional benefit',
    line_of_therapy: '1L',
    partner: 'BioMarin (co-development and co-commercialization)',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Only approved ERT for MPS I; addresses somatic disease burden',
      'Demonstrated improvement in respiratory function and exercise capacity',
      'Over 20 years of clinical use with established safety profile',
    ],
    weaknesses: [
      'Weekly IV infusions of 3-4 hours; high treatment burden',
      'Does not cross blood-brain barrier; limited benefit for CNS disease in severe Hurler',
      'Antibody development common; may attenuate efficacy over time',
    ],
    source: 'FDA label; Wraith et al., J Pediatr 2004; Phase 3 (NCT00146770)',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Hematopoietic stem cell transplantation (HSCT)',
    company: 'Standard of care (multiple transplant centers)',
    indication: 'Hurler Syndrome',
    indication_specifics: 'Severe MPS I (Hurler syndrome) in children <2.5 years; HSCT is standard of care for CNS disease prevention',
    mechanism: 'Allogeneic HSCT provides donor-derived enzyme-producing cells that cross blood-brain barrier',
    mechanism_category: 'cell_therapy',
    molecular_target: 'Alpha-L-iduronidase (IDUA) — engrafted donor cells produce enzyme',
    phase: 'Approved',
    primary_endpoint: 'Neurodevelopmental outcomes (DQ/IQ preservation); overall survival; enzyme activity levels',
    key_data: 'Standard of care for severe Hurler since 1980s; successful HSCT before age 2.5 years preserves cognitive function and extends survival to 20+ years; engraftment rates >90% with modern conditioning; busulfan-based myeloablative conditioning preferred; combined with ERT peri-transplant',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Only treatment that addresses CNS manifestations of severe Hurler syndrome',
      'Sustained enzyme production from engrafted donor cells; potentially curative',
      'Decades of transplant experience with improving survival outcomes',
    ],
    weaknesses: [
      'Significant transplant-related morbidity and mortality (5-15% TRM)',
      'Requires suitable donor; outcome varies with donor source and engraftment',
      'Must be performed early (<2.5 years) before irreversible CNS damage occurs',
    ],
    source: 'Aldenhoven et al., Blood 2015; Boelens et al., Bone Marrow Transplant 2014; ASBMT guidelines',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // NIEMANN-PICK DISEASE TYPE C
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Miplyffa',
    generic_name: 'arimoclomol',
    company: 'Zevra Therapeutics (formerly IntraBio)',
    indication: 'Niemann-Pick Disease Type C',
    indication_specifics: 'Niemann-Pick disease type C (NPC) in adult and pediatric patients >=2 years',
    mechanism: 'Co-inducer of heat shock protein response; amplifies HSP70 expression to enhance protein folding and lysosomal function',
    mechanism_category: 'heat_shock_protein_amplifier',
    molecular_target: 'HSF-1 / HSP70 pathway',
    phase: 'Approved',
    primary_endpoint: '5-domain NPC Clinical Severity Scale (NPC-CSS)',
    key_data: 'FDA approved 2024; pivotal trial demonstrated slower disease progression on NPC-CSS vs. standard of care; first disease-modifying therapy approved for NPC; oral capsule formulation',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First and only FDA-approved disease-modifying therapy for NPC',
      'Oral administration; practical for chronic use in pediatric and adult patients',
      'Addresses a devastating neurodegenerative disease with no prior approved options',
    ],
    weaknesses: [
      'Modest effect size on NPC-CSS; does not halt disease progression',
      'Ultra-small patient population (~1 in 120,000-150,000) limits commercial potential',
      'Previously received FDA complete response letter before ultimate approval; complex regulatory path',
    ],
    source: 'FDA label; Zevra Therapeutics prescribing information; Kirkegaard et al., Sci Transl Med 2016',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Zavesca (off-label)',
    generic_name: 'miglustat',
    company: 'Actelion (Johnson & Johnson)',
    indication: 'Niemann-Pick Disease Type C',
    indication_specifics: 'NPC — off-label use in US; EU-approved for neurological manifestations of NPC',
    mechanism: 'Glucosylceramide synthase inhibitor; substrate reduction therapy reducing glycosphingolipid accumulation',
    mechanism_category: 'substrate_reduction_therapy',
    molecular_target: 'Glucosylceramide synthase',
    phase: 'Approved',
    primary_endpoint: 'Horizontal saccadic eye movement velocity (HSEM); NPC disability scale',
    key_data: 'EMA approved for NPC 2009 (off-label in US); OGT 918-007 trial: stabilization of HSEM (p=0.028 vs. untreated) and swallowing function over 12 months; widely used off-label in US before Miplyffa approval; GI side effects limit tolerability',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Over 15 years of clinical experience in NPC (EU-approved, off-label US)',
      'Oral formulation with established dosing in pediatric and adult NPC',
      'Stabilizes neurological function including saccadic eye movements and swallowing',
    ],
    weaknesses: [
      'Not FDA-approved for NPC (off-label use); reimbursement challenges in US',
      'GI side effects (diarrhea, bloating, weight loss) common and dose-limiting',
      'Substrate reduction only partially addresses complex sphingolipid trafficking defect in NPC',
    ],
    source: 'EMA SmPC; OGT 918-007 trial; Patterson et al., Lancet Neurol 2007; Wraith et al., Mol Genet Metab 2010',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // BATTEN DISEASE (NEURONAL CEROID LIPOFUSCINOSIS)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Brineura',
    generic_name: 'cerliponase alfa',
    company: 'BioMarin Pharmaceutical',
    indication: 'Batten Disease',
    indication_specifics: 'CLN2 disease (late infantile neuronal ceroid lipofuscinosis type 2; TPP1 deficiency) in patients 3 years and older',
    mechanism: 'Recombinant tripeptidyl peptidase 1 (TPP1) enzyme replacement therapy delivered intracerebroventricularly',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Tripeptidyl peptidase 1 (TPP1)',
    phase: 'Approved',
    primary_endpoint: 'Rate of decline on CLN2 Clinical Rating Scale (motor and language domains)',
    key_data: 'FDA approved 2017; first ERT delivered directly to the brain; pivotal study: treated patients declined 0.27 points/48 weeks on CLN2 scale vs. 2.12 points/48 weeks in natural history cohort (p<0.001); slowed but did not halt neurodegeneration',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First intracerebroventricular ERT; breakthrough route of administration for CNS enzyme delivery',
      'Dramatically slowed disease progression vs. devastating natural history',
      'Demonstrated proof of concept for CNS enzyme replacement in lysosomal storage diseases',
    ],
    weaknesses: [
      'Requires surgical implantation of intracerebroventricular access device',
      'Biweekly ICV infusions (~4 hours in medical facility); extreme treatment burden',
      'Ultra-orphan pricing (~$700,000+/year); only ~1,000 CLN2 patients worldwide',
    ],
    source: 'FDA label; Schulz et al., NEJM 2018; BioMarin prescribing information',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'No approved therapy (other NCL forms)',
    company: 'N/A — unmet medical need',
    indication: 'Batten Disease',
    indication_specifics: 'CLN1, CLN3, CLN5-CLN14 forms of neuronal ceroid lipofuscinosis; no approved therapies exist',
    mechanism: 'No disease-modifying therapies available; management is supportive/palliative',
    mechanism_category: 'supportive_care',
    phase: 'Preclinical',
    primary_endpoint: 'N/A — multiple gene therapy and small molecule programs in preclinical/early clinical',
    key_data: 'CLN3 (juvenile Batten) is most common form; gene therapy approaches in development (Weill Cornell AAV9-CLN3, NCT03770572); CLN1 and CLN6 gene therapy programs also advancing; no programs beyond Phase 1/2',
    line_of_therapy: '1L',
    nct_ids: ['NCT03770572'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Active gene therapy pipeline across multiple CLN subtypes',
      'Strong academic research community driving therapeutic development',
      'Regulatory incentives (orphan drug, rare pediatric disease voucher) support development',
    ],
    weaknesses: [
      'No approved therapies for any NCL form beyond CLN2',
      'Extreme rarity of individual subtypes limits trial enrollment and commercial viability',
      'CNS delivery challenges remain for all gene therapy approaches',
    ],
    source: 'ClinicalTrials.gov; NCL Resource Foundation; Mole & Cotman, Biochim Biophys Acta 2015',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // EPIDERMOLYSIS BULLOSA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Vyjuvek',
    generic_name: 'beremagene geperpavec',
    company: 'Krystal Biotech',
    indication: 'Epidermolysis Bullosa',
    indication_specifics: 'Dystrophic epidermolysis bullosa (DEB) in patients 6 months and older with mutations in COL7A1',
    mechanism: 'Topical HSV-1 based gene therapy delivering functional COL7A1 transgene to wound keratinocytes',
    mechanism_category: 'gene_therapy',
    molecular_target: 'COL7A1 (type VII collagen)',
    phase: 'Approved',
    primary_endpoint: 'Complete wound closure of paired wounds at 6 months (treated vs. placebo)',
    key_data: 'FDA approved 2023 (first topical gene therapy, first redosable gene therapy); GEM-3 Phase 3: 67% complete wound closure at 6 months vs. 22% placebo (p=0.002); repeat application enabled by non-integrating HSV-1 vector',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First and only FDA-approved gene therapy for any dermatological condition',
      'Topical gel application; non-invasive and redosable unlike AAV-based gene therapies',
      'Demonstrated restoration of type VII collagen and anchoring fibrils at wound sites',
    ],
    weaknesses: [
      'Requires repeated applications to maintain collagen production',
      'Only addresses wound healing; does not prevent new blistering',
      'Annual cost ~$25,000-50,000 per treatment course; cumulative cost can be significant',
    ],
    source: 'FDA label; GEM-3 trial (NCT04491604); Guide et al., NEJM 2022',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'FILSUVEZ',
    generic_name: 'birch bark extract (betulin)',
    company: 'Amryt Pharma (Chiesi Group)',
    indication: 'Epidermolysis Bullosa',
    indication_specifics: 'Partial-thickness wounds in EB patients aged 6 months and older (junctional and dystrophic EB)',
    mechanism: 'Birch bark triterpene extract; promotes wound healing via anti-inflammatory and pro-epithelialization activity',
    mechanism_category: 'wound_healing_agent',
    molecular_target: 'Non-specific — multi-target anti-inflammatory and pro-regenerative activity',
    phase: 'Approved',
    primary_endpoint: 'Time to first complete closure of target wound',
    key_data: 'EMA approved 2022; FDA approved 2023; EASE Phase 3: improved wound healing by day 45 (41.3% vs. 28.9% vehicle, adjusted rate ratio 1.44); first topical approved specifically for EB wound management; well-tolerated gel formulation',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First non-gene-therapy topical approved for EB wound management',
      'Simple gel application; well-tolerated with low adverse event rate',
      'Addresses day-to-day wound care burden across EB subtypes',
    ],
    weaknesses: [
      'Does not address underlying genetic defect; symptomatic wound care only',
      'Modest effect size; incremental wound healing improvement over standard wound care',
      'Does not prevent new blister formation or disease progression',
    ],
    source: 'FDA/EMA labels; EASE trial (NCT03068780); Kern et al., Br J Dermatol 2023',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // ACHONDROPLASIA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Voxzogo',
    generic_name: 'vosoritide',
    company: 'BioMarin Pharmaceutical',
    indication: 'Achondroplasia',
    indication_specifics: 'Achondroplasia in pediatric patients aged 5 years and older with open growth plates',
    mechanism: 'C-type natriuretic peptide (CNP) analog; counteracts FGFR3 overactivation to restore endochondral bone growth',
    mechanism_category: 'growth_factor_analog',
    molecular_target: 'Natriuretic peptide receptor B (NPR-B) — downstream antagonism of FGFR3 signaling',
    phase: 'Approved',
    primary_endpoint: 'Annualized growth velocity (AGV) change from baseline',
    key_data: 'FDA approved 2021; Phase 3 Study 111-301: mean AGV increase of 1.57 cm/year vs. placebo (5.70 vs. 4.13 cm/year, p<0.0001) over 52 weeks; sustained efficacy through 4+ years of extension data; well-tolerated daily SC injection',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First and only pharmacological therapy for achondroplasia',
      'Clinically meaningful increase in annualized growth velocity sustained over years',
      'Well-tolerated; most AEs are transient injection site reactions and blood pressure decreases',
    ],
    weaknesses: [
      'Daily subcutaneous injection in pediatric patients; compliance challenges',
      'Transient blood pressure decreases require monitoring; injection must be given with food',
      'Limited to patients with open growth plates; not indicated for adults',
    ],
    source: 'FDA label; Study 111-301 (NCT03197766); Savarirayan et al., Lancet 2020',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'No other approved therapy',
    company: 'N/A — Voxzogo is only approved pharmacotherapy',
    indication: 'Achondroplasia',
    indication_specifics: 'No other pharmacological therapies approved; historical SOC is orthopedic management and limb-lengthening surgery',
    mechanism: 'Supportive care: surgical limb lengthening, spinal decompression, growth hormone (off-label, not effective)',
    mechanism_category: 'supportive_care',
    phase: 'Approved',
    primary_endpoint: 'N/A — surgical outcomes; height gain from limb lengthening',
    key_data: 'Limb-lengthening surgery can add 10-15 cm height but requires multiple surgeries over 1-2 years with prolonged recovery; growth hormone not effective in achondroplasia; pipeline: infigratinib (FGFR1-3 inhibitor, QED Therapeutics) Phase 2 for achondroplasia',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Limb-lengthening surgery provides definitive height gain',
      'Orthopedic interventions can address specific complications (spinal stenosis, genu varum)',
      'Pipeline FGFR inhibitor (infigratinib) may offer oral alternative mechanism',
    ],
    weaknesses: [
      'Limb-lengthening surgery is highly invasive with significant pain and complication risk',
      'Growth hormone has shown minimal efficacy in achondroplasia',
      'No systemic pharmacotherapy alternative to Voxzogo currently available',
    ],
    source: 'Hoover-Fong et al., Am J Med Genet 2020; QED Therapeutics pipeline disclosures',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // HYPOPHOSPHATASIA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Strensiq',
    generic_name: 'asfotase alfa',
    company: 'Alexion (AstraZeneca)',
    indication: 'Hypophosphatasia',
    indication_specifics: 'Perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)',
    mechanism: 'Bone-targeted enzyme replacement therapy; Fc-deca-aspartate fusion of tissue-nonspecific alkaline phosphatase (TNSALP)',
    mechanism_category: 'enzyme_replacement_therapy',
    molecular_target: 'Tissue-nonspecific alkaline phosphatase (TNSALP / ALPL)',
    phase: 'Approved',
    primary_endpoint: 'Overall survival at 5 years (perinatal/infantile); radiographic healing on Radiographic Global Impression of Change (RGI-C)',
    key_data: 'FDA approved 2015; in perinatal/infantile HPP: 84% overall survival at 5 years vs. 27% in historical controls; significant radiographic healing (RGI-C +2.3 vs. historical baseline); in juvenile HPP: improved growth and physical function scores',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Only approved therapy for HPP; dramatic survival benefit in perinatal/infantile disease',
      'Bone-targeted design via deca-aspartate domain provides tissue-specific enzyme delivery',
      'Significant radiographic healing and functional improvement across age groups',
    ],
    weaknesses: [
      'Up to 6 SC injections per week; extremely high treatment burden',
      'Injection site reactions including lipodystrophy and localized calcification',
      'Annual cost ~$300,000-800,000 depending on weight; lifetime treatment required',
    ],
    source: 'FDA label; Whyte et al., NEJM 2012; Alexion prescribing information',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Supportive care',
    company: 'Standard of care',
    indication: 'Hypophosphatasia',
    indication_specifics: 'Non-pharmacological management of HPP including orthopedic care, respiratory support, and dental management',
    mechanism: 'Supportive measures: non-steroidal anti-inflammatories, physical therapy, fracture management, dental prosthetics; vitamin B6 for seizures in perinatal form',
    mechanism_category: 'supportive_care',
    phase: 'Approved',
    primary_endpoint: 'N/A — symptom management',
    key_data: 'Prior to Strensiq, perinatal HPP was nearly universally fatal (~73% mortality by age 5); supportive care remains essential as adjunct to ERT; includes respiratory support (ventilator in severe cases), orthopedic management of fractures and deformity, craniosynostosis surgery, and dental management for premature tooth loss',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Essential complement to ERT; addresses complications across organ systems',
      'Multidisciplinary care improves quality of life and functional outcomes',
      'Respiratory and orthopedic interventions are life-saving in severe cases',
    ],
    weaknesses: [
      'Cannot address underlying enzyme deficiency',
      'Without ERT, supportive care alone is insufficient for severe forms',
      'Chronic fractures and skeletal deformity progress despite best supportive care',
    ],
    source: 'Whyte, Clin Rev Bone Miner Metab 2016; Mornet et al., Metabolism 2018',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // ALPHA-1 ANTITRYPSIN DEFICIENCY
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Zemaira',
    generic_name: 'alpha-1 proteinase inhibitor (human)',
    company: 'CSL Behring',
    indication: 'Alpha-1 Antitrypsin Deficiency',
    indication_specifics: 'Chronic augmentation and maintenance therapy in adults with emphysema due to alpha-1 antitrypsin deficiency',
    mechanism: 'Plasma-derived alpha-1 proteinase inhibitor (A1PI) augmentation therapy; raises serum and lung epithelial lining fluid A1PI levels above protective threshold (11 micromol/L)',
    mechanism_category: 'protein_augmentation_therapy',
    molecular_target: 'Alpha-1 proteinase inhibitor (alpha-1 antitrypsin / SERPINA1)',
    phase: 'Approved',
    primary_endpoint: 'Serum A1PI trough levels >=11 micromol/L (protective threshold)',
    key_data: 'FDA approved 2003; demonstrated achievement and maintenance of A1PI levels above protective threshold with weekly IV infusions; RAPID trial (pooled A1PI data): 34% reduction in rate of lung density loss by CT densitometry vs. placebo (p=0.03)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Well-established augmentation therapy with robust pharmacokinetic profile',
      'RAPID trial evidence showing slowed lung density decline',
      'Self-infusion at home feasible with proper training; reduces clinic visits',
    ],
    weaknesses: [
      'Weekly IV infusions for life; significant treatment burden',
      'Plasma-derived product; dependent on donor plasma supply',
      'Does not restore normal A1PI levels; slows but does not halt emphysema progression',
    ],
    source: 'FDA label; RAPID trial (NCT00261833); Chapman et al., Lancet 2015',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Glassia',
    generic_name: 'alpha-1 proteinase inhibitor (human), liquid',
    company: 'Takeda (Kamada)',
    indication: 'Alpha-1 Antitrypsin Deficiency',
    indication_specifics: 'Chronic augmentation and maintenance therapy for emphysema due to A1AT deficiency; ready-to-use liquid formulation',
    mechanism: 'Plasma-derived alpha-1 proteinase inhibitor augmentation therapy; ready-to-use liquid formulation not requiring reconstitution',
    mechanism_category: 'protein_augmentation_therapy',
    molecular_target: 'Alpha-1 proteinase inhibitor (alpha-1 antitrypsin / SERPINA1)',
    phase: 'Approved',
    primary_endpoint: 'Serum A1PI trough levels >=11 micromol/L; non-inferiority to Prolastin-C',
    key_data: 'FDA approved 2010; demonstrated non-inferior A1PI trough levels vs. Prolastin-C; first and only liquid ready-to-use A1PI product; eliminates reconstitution step, reducing preparation time from ~20 minutes to <5 minutes; also approved for SC self-administration (2023 supplement)',
    line_of_therapy: '1L',
    partner: 'Kamada Ltd. (manufacturing)',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Only liquid ready-to-use formulation; no reconstitution required',
      'SC self-administration option (2023 approval) significantly improves convenience',
      'Non-inferior efficacy to established A1PI products with simplified preparation',
    ],
    weaknesses: [
      'Requires cold chain storage (2-8C) which limits portability',
      'Plasma-derived with same supply and theoretical pathogen risks as other products',
      'SC administration route requires higher injection volumes and frequency adjustment',
    ],
    source: 'FDA label; Glassia prescribing information; Kamada/Takeda clinical data',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // PRADER-WILLI SYNDROME
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Growth hormone therapy',
    generic_name: 'somatropin',
    company: 'Multiple (Pfizer/Genotropin, Novo Nordisk/Norditropin, others)',
    indication: 'Prader-Willi Syndrome',
    indication_specifics: 'Growth failure and body composition improvement in pediatric PWS patients',
    mechanism: 'Recombinant human growth hormone; improves linear growth, body composition (reduces fat mass, increases lean mass), and potentially cognitive function',
    mechanism_category: 'hormone_replacement_therapy',
    molecular_target: 'Growth hormone receptor (GHR)',
    phase: 'Approved',
    primary_endpoint: 'Height velocity; body composition (lean mass / fat mass ratio)',
    key_data: 'FDA approved for PWS (Genotropin 2000); multiple RCTs demonstrate improved height velocity (+8-10 cm/year first year), reduced fat mass (-10-15%), increased lean mass, improved motor development; does NOT address hyperphagia, the most debilitating symptom; sleep apnea screening required before initiation',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Only FDA-approved pharmacotherapy for PWS; standard of care with decades of evidence',
      'Significant improvement in body composition, height, and motor development',
      'May improve cognitive function and quality of life measures in addition to growth',
    ],
    weaknesses: [
      'Does not address hyperphagia — the most challenging clinical feature of PWS',
      'Daily SC injection required; compliance can be challenging in behavioral context of PWS',
      'Risk of sleep apnea exacerbation; requires polysomnography before and during treatment',
    ],
    source: 'FDA label (Genotropin); Carrel et al., J Clin Endocrinol Metab 2004; Deal et al., J Clin Endocrinol Metab 2013',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Setmelanotide (pipeline for PWS)',
    generic_name: 'setmelanotide',
    company: 'Rhythm Pharmaceuticals',
    indication: 'Prader-Willi Syndrome',
    indication_specifics: 'Hyperphagia and obesity in PWS; investigational (approved for other genetic obesity syndromes under brand name IMCIVREE)',
    mechanism: 'MC4R agonist; activates melanocortin-4 receptor in hypothalamus to reduce hunger and increase satiety signaling',
    mechanism_category: 'receptor_agonist',
    molecular_target: 'Melanocortin-4 receptor (MC4R)',
    phase: 'Phase 3',
    primary_endpoint: 'Change in hyperphagia questionnaire score; percent change in BMI',
    key_data: 'IMCIVREE approved for POMC, PCSK1, LEPR obesity (2020); Phase 3 trial in PWS (EMANATE, NCT05093634) ongoing; Phase 2 data in PWS showed trends in hunger reduction but did not meet primary endpoint in earlier studies; mechanism may be less effective in PWS vs. monogenic obesity',
    line_of_therapy: '1L',
    nct_ids: ['NCT05093634'],
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'MC4R pathway is directly relevant to hypothalamic obesity in PWS',
      'Already approved for other genetic obesity disorders; known safety profile',
      'Addresses hyperphagia — the greatest unmet need in PWS management',
    ],
    weaknesses: [
      'Earlier Phase 2 data in PWS were inconclusive; complex genetics of PWS hunger may limit MC4R approach',
      'PWS hyperphagia involves multiple hypothalamic pathways beyond MC4R signaling',
      'Injection site reactions and skin hyperpigmentation are class effects',
    ],
    source: 'ClinicalTrials.gov (NCT05093634); IMCIVREE FDA label; Rhythm Pharmaceuticals pipeline disclosures',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // TUBEROUS SCLEROSIS COMPLEX
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Afinitor',
    generic_name: 'everolimus',
    company: 'Novartis',
    indication: 'Tuberous Sclerosis Complex',
    indication_specifics: 'TSC-associated subependymal giant cell astrocytoma (SEGA) and renal angiomyolipoma; also adjunctive for TSC-associated refractory partial-onset seizures',
    mechanism: 'mTOR inhibitor; inhibits mTORC1 complex to suppress cell growth in TSC1/TSC2-mutant cells',
    mechanism_category: 'mtor_inhibitor',
    molecular_target: 'mTOR (mechanistic target of rapamycin) — mTORC1 complex',
    phase: 'Approved',
    primary_endpoint: 'SEGA volume reduction >=50%; renal AML volume reduction >=50%; seizure frequency reduction',
    key_data: 'FDA approved for TSC-SEGA (2010), TSC-AML (2012), TSC-seizures (2018); EXIST-1 (SEGA): 35% achieved >=50% reduction vs. 0% placebo; EXIST-2 (AML): 42% response rate vs. 0% placebo; EXIST-3 (seizures): 40% seizure reduction at 18 weeks',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Addresses three major TSC manifestations (SEGA, AML, seizures) with one drug',
      'Directly targets dysregulated mTOR pathway in TSC1/TSC2-mutant cells',
      'Extensive clinical trial program (EXIST-1, -2, -3) with strong efficacy data',
    ],
    weaknesses: [
      'Chronic immunosuppression with risk of infections (stomatitis, pneumonitis common)',
      'Requires therapeutic drug monitoring; narrow therapeutic window',
      'Tumor regrowth occurs upon treatment discontinuation; lifelong therapy needed',
    ],
    source: 'FDA label; EXIST-1 (NCT00789828); EXIST-2 (NCT00790400); EXIST-3 (NCT01713946); Franz et al., Lancet 2013',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Sabril',
    generic_name: 'vigabatrin',
    company: 'Lundbeck',
    indication: 'Tuberous Sclerosis Complex',
    indication_specifics: 'Infantile spasms (IS) in patients 1 month to 2 years; specifically TSC-associated infantile spasms where it is first-line',
    mechanism: 'Irreversible GABA-transaminase inhibitor; increases GABA concentrations in the brain',
    mechanism_category: 'gaba_modulator',
    molecular_target: 'GABA-transaminase (irreversible inhibition)',
    phase: 'Approved',
    primary_endpoint: 'Cessation of infantile spasms (spasm-free days); EEG normalization (resolution of hypsarrhythmia)',
    key_data: 'FDA approved 2009; in TSC-associated infantile spasms: 73-96% response rate (spasm freedom) vs. ~50-60% for hormonal therapy (ACTH); considered first-line for TSC-associated IS per international consensus; REMS required due to progressive bilateral visual field defects',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First-line therapy for TSC-associated infantile spasms per international consensus',
      'Very high response rate (73-96%) specifically in TSC-IS population',
      'Oral formulation (powder for oral solution); easier to administer than ACTH injections',
    ],
    weaknesses: [
      'Progressive irreversible bilateral concentric visual field constriction (30-40% of patients)',
      'REMS program (SHARE) required for prescribing; mandatory ophthalmologic monitoring',
      'Potential for sedation, weight gain, and behavioral changes',
    ],
    source: 'FDA label; Hancock et al., Cochrane Review 2013; Vigevano & Cilio, Epilepsia 1997; Chiron et al., Lancet 1997',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // SPINAL AND BULBAR MUSCULAR ATROPHY (KENNEDY DISEASE)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'No approved therapy — pipeline: androgen receptor degraders',
    company: 'Multiple (Ionis, Biogen, academic centers)',
    indication: 'Spinal and Bulbar Muscular Atrophy',
    indication_specifics: 'SBMA (Kennedy disease); no FDA-approved disease-modifying therapy; pipeline focuses on AR protein clearance',
    mechanism: 'Targeted protein degradation of mutant androgen receptor (polyQ-expanded AR); proteolysis-targeting chimeras (PROTACs) and selective AR degraders',
    mechanism_category: 'targeted_protein_degradation',
    molecular_target: 'Androgen receptor (AR) — polyglutamine expansion mutant',
    phase: 'Preclinical',
    primary_endpoint: 'N/A — preclinical programs targeting mutant AR protein levels and motor neuron survival',
    key_data: 'SBMA is caused by CAG repeat expansion in AR gene; mutant AR aggregates in motor neurons; leuprorelin (androgen deprivation) showed partial benefit in Japanese Phase 3 but failed in Western trials; AR-targeted degraders are in preclinical development at multiple groups; dutasteride and exercise interventions studied but not disease-modifying',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'PROTAC technology enables selective degradation of mutant AR while sparing normal protein',
      'Clear molecular target (polyQ-expanded AR) with well-understood disease mechanism',
      'Strong preclinical data in AR-dependent cellular and animal models',
    ],
    weaknesses: [
      'No candidates in clinical trials yet; long timeline to any potential approval',
      'Systemic AR degradation may cause anti-androgenic side effects (gynecomastia, erectile dysfunction)',
      'Very small patient population (~1 in 40,000 males) limits commercial attractiveness',
    ],
    source: 'Katsuno et al., Lancet Neurol 2012; Hashizume et al., Lancet Neurol 2016; NINDS SBMA research program',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'No approved therapy — pipeline: antisense oligonucleotides',
    company: 'Ionis Pharmaceuticals',
    indication: 'Spinal and Bulbar Muscular Atrophy',
    indication_specifics: 'SBMA (Kennedy disease); ASO approaches targeting AR mRNA to reduce mutant AR expression',
    mechanism: 'Antisense oligonucleotide targeting AR pre-mRNA; reduces expression of both normal and mutant androgen receptor',
    mechanism_category: 'antisense_oligonucleotide',
    molecular_target: 'AR mRNA (androgen receptor pre-mRNA)',
    phase: 'Phase 1',
    primary_endpoint: 'Safety, tolerability, pharmacokinetics; AR protein reduction in target tissues',
    key_data: 'Ionis has ASO programs targeting AR for multiple indications including SBMA; preclinical studies in SBMA mouse models showed reduced mutant AR aggregation and improved motor function; ASO approach leverages proven platform (Spinraza precedent in SMA); Phase 1/2 trials expected',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'ASO platform well-validated with Spinraza (SMA) and multiple approved products',
      'Directly reduces toxic mutant AR protein production at mRNA level',
      'Intrathecal delivery can target motor neurons in spinal cord',
    ],
    weaknesses: [
      'Intrathecal delivery requires lumbar puncture; challenging for chronic administration',
      'Non-selective AR knockdown may cause androgen insensitivity syndrome symptoms',
      'Early-stage; efficacy in humans unproven; may require allele-selective approach',
    ],
    source: 'Ionis Pharmaceuticals pipeline disclosures; Lieberman et al., Neurotherapeutics 2014; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Juxtapid',
    generic_name: 'lomitapide',
    company: 'Amryt Pharma (Chiesi Group)',
    indication: 'Homozygous Familial Hypercholesterolemia',
    indication_specifics: 'HoFH as adjunct to lipid-lowering therapies and diet in adults',
    mechanism: 'Microsomal triglyceride transfer protein (MTP) inhibitor; blocks hepatic VLDL assembly and secretion',
    mechanism_category: 'small_molecule_inhibitor',
    molecular_target: 'Microsomal triglyceride transfer protein (MTP)',
    phase: 'Approved',
    primary_endpoint: 'Percent change in LDL-C from baseline',
    key_data: 'FDA approved 2012; single-arm Phase 3: mean LDL-C reduction of 50% at week 26 (from 336 to 166 mg/dL); 8 of 29 patients achieved LDL-C <100 mg/dL; REMS required due to hepatotoxicity risk; must be used with low-fat diet (<20% calories from fat)',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Effective in HoFH regardless of LDL receptor status (null/null, null/defective, defective/defective)',
      'Oral therapy; 50% LDL-C reduction even in patients with no functional LDL receptors',
      'LDL receptor-independent mechanism complements other lipid-lowering therapies',
    ],
    weaknesses: [
      'REMS program required for hepatotoxicity risk; hepatic fat accumulation (steatosis)',
      'Severe GI side effects (diarrhea, nausea, vomiting) common and dose-limiting',
      'Requires very low-fat diet (<20% calories from fat); significant lifestyle restriction',
    ],
    source: 'FDA label; Cuchel et al., Lancet 2013; Phase 3 (NCT00730236)',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Evkeeza',
    generic_name: 'evinacumab',
    company: 'Regeneron Pharmaceuticals',
    indication: 'Homozygous Familial Hypercholesterolemia',
    indication_specifics: 'HoFH as adjunct to other LDL-C lowering therapies in patients 5 years and older',
    mechanism: 'Fully human monoclonal antibody against angiopoietin-like 3 (ANGPTL3); reduces LDL-C via LDLR-independent pathway',
    mechanism_category: 'monoclonal_antibody',
    molecular_target: 'ANGPTL3 (angiopoietin-like protein 3)',
    phase: 'Approved',
    primary_endpoint: 'Percent change in LDL-C from baseline at week 24',
    key_data: 'FDA approved 2021; ELIPSE HoFH Phase 3: 47.1% LDL-C reduction vs. 1.9% increase with placebo (p<0.001); effective in LDLR-null HoFH patients (reduction of 43.4%); monthly IV infusion; no REMS required',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Highly effective in both LDLR-null and LDLR-defective HoFH genotypes',
      'ANGPTL3 inhibition: novel LDL-independent mechanism reduces LDL-C, TG, and Lp(a)',
      'No hepatic fat accumulation signal; better hepatic safety profile than lomitapide',
    ],
    weaknesses: [
      'Monthly IV infusion at healthcare facility; not self-administered',
      'Annual cost ~$450,000; extremely high even for orphan drug',
      'Nascent drug class; limited long-term cardiovascular outcomes data in HoFH',
    ],
    source: 'FDA label; ELIPSE HoFH trial (NCT03399786); Raal et al., NEJM 2020',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Repatha',
    generic_name: 'evolocumab',
    company: 'Amgen',
    indication: 'Homozygous Familial Hypercholesterolemia',
    indication_specifics: 'HoFH adjunct to diet and other LDL-lowering therapies in patients 10 years and older',
    mechanism: 'Fully human monoclonal antibody against PCSK9; increases LDL receptor recycling to hepatocyte surface',
    mechanism_category: 'monoclonal_antibody',
    molecular_target: 'PCSK9 (proprotein convertase subtilisin/kexin type 9)',
    phase: 'Approved',
    primary_endpoint: 'Percent change in LDL-C from baseline',
    key_data: 'FDA approved for HoFH 2017; TAUSSIG study: mean LDL-C reduction of 20.6% in HoFH at 48 weeks (420mg monthly SC); response depends on residual LDL receptor function — minimal/no effect in LDLR-null patients; FOURIER outcomes trial demonstrated CV benefit in broader population',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Self-administered SC injection (monthly or biweekly); convenient home use',
      'Cardiovascular outcomes data from FOURIER trial support LDL-lowering benefit',
      'Established PCSK9 inhibitor class with broad physician familiarity and payer acceptance',
    ],
    weaknesses: [
      'Limited efficacy in LDLR-null HoFH patients (requires some residual receptor function)',
      'Modest LDL-C reduction (~20%) in HoFH vs. ~60% in non-FH populations',
      'Less effective than evinacumab or lomitapide in patients with severe LDLR mutations',
    ],
    source: 'FDA label; TAUSSIG study (NCT01624142); FOURIER trial; Raal et al., Lancet 2017',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // CONGENITAL ADRENAL HYPERPLASIA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Hydrocortisone / Fludrocortisone',
    generic_name: 'hydrocortisone + fludrocortisone',
    company: 'Multiple generic manufacturers',
    indication: 'Congenital Adrenal Hyperplasia',
    indication_specifics: 'Classic and non-classic CAH due to 21-hydroxylase deficiency; glucocorticoid + mineralocorticoid replacement',
    mechanism: 'Physiologic cortisol replacement (hydrocortisone) + mineralocorticoid replacement (fludrocortisone) to suppress ACTH-driven androgen excess',
    mechanism_category: 'hormone_replacement_therapy',
    molecular_target: 'Glucocorticoid receptor + mineralocorticoid receptor',
    phase: 'Approved',
    primary_endpoint: '17-hydroxyprogesterone (17-OHP) and androstenedione normalization; growth velocity; bone age',
    key_data: 'Standard of care for >60 years; hydrocortisone (10-15 mg/m2/day in children, divided TID) suppresses ACTH and adrenal androgens; fludrocortisone (0.05-0.2 mg/day) replaces aldosterone in salt-wasting forms; chronic supraphysiologic dosing required to suppress androgens causes iatrogenic Cushing syndrome',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Decades of clinical experience; well-understood pharmacology and dosing',
      'Lifesaving in salt-wasting CAH; prevents adrenal crises',
      'Inexpensive and widely available as generic medications',
    ],
    weaknesses: [
      'Chronic supraphysiologic glucocorticoid dosing causes growth suppression, obesity, metabolic syndrome',
      'Narrow therapeutic window: under-replacement causes virilization, over-replacement causes Cushingoid features',
      'TID dosing with poor overnight cortisol coverage; early morning ACTH surge drives androgen escape',
    ],
    source: 'Endocrine Society Clinical Practice Guidelines 2018; Speiser et al., J Clin Endocrinol Metab 2018',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Crinecerfont',
    generic_name: 'crinecerfont',
    company: 'Neurocrine Biosciences',
    indication: 'Congenital Adrenal Hyperplasia',
    indication_specifics: 'Classic CAH due to 21-hydroxylase deficiency; oral CRF1 receptor antagonist to reduce ACTH-driven androgen excess',
    mechanism: 'Corticotropin-releasing factor type 1 (CRF1) receptor antagonist; blocks CRH-driven ACTH secretion to reduce adrenal androgen production without supraphysiologic glucocorticoids',
    mechanism_category: 'receptor_antagonist',
    molecular_target: 'CRF1 receptor (corticotropin-releasing factor receptor 1)',
    phase: 'Phase 3',
    primary_endpoint: 'Androstenedione normalization with concurrent glucocorticoid dose reduction',
    key_data: 'Phase 3 CAHtalyst trial (adults): met primary endpoint with significant androstenedione reduction while enabling 50%+ glucocorticoid dose reduction; Phase 3 pediatric trial (CAHptain) also met primary endpoint; FDA submission expected 2025; potential to transform CAH management by reducing glucocorticoid burden',
    line_of_therapy: '1L',
    nct_ids: ['NCT04490915', 'NCT05451316'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Paradigm-shifting approach: reduces glucocorticoid dose while maintaining androgen control',
      'Both adult and pediatric Phase 3 trials met primary endpoints',
      'Oral BID dosing; addresses root cause of ACTH excess rather than downstream suppression',
    ],
    weaknesses: [
      'Not yet approved; regulatory submission and review timeline pending',
      'Does not eliminate need for glucocorticoids entirely; still requires some replacement',
      'Long-term effects of chronic CRF1 antagonism unknown (potential stress response implications)',
    ],
    source: 'CAHtalyst trial (NCT04490915); CAHptain trial (NCT05451316); Neurocrine Biosciences pipeline disclosures 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Upstaza',
    generic_name: 'eladocagene exuparvovec',
    company: 'PTC Therapeutics',
    indication: 'Aromatic L-Amino Acid Decarboxylase Deficiency',
    indication_specifics: 'AADC deficiency in patients 18 months and older; AAV2-based gene therapy delivered via intraputaminal infusion',
    mechanism: 'AAV2-based gene therapy delivering functional DDC gene (encoding AADC enzyme) directly to putamen neurons',
    mechanism_category: 'gene_therapy',
    molecular_target: 'DDC gene (dopa decarboxylase / aromatic L-amino acid decarboxylase)',
    phase: 'Approved',
    primary_endpoint: 'Motor milestone achievement (head control, sitting, standing, walking); Peabody Developmental Motor Scales (PDMS-2)',
    key_data: 'EMA approved 2022 (first centrally approved AAV gene therapy in EU); FDA approved 2023; pivotal study: 25/26 patients achieved head control, 22/26 achieved sitting independently — milestones never previously achieved; significant improvement in oculogyric crises (from ~7/month to near-zero); single neurosurgical procedure',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Potentially curative: one-time gene therapy restores AADC enzyme in CNS',
      'Transformative motor milestone gains in patients with essentially no voluntary movement',
      'Near-elimination of oculogyric crises — the most disabling symptom',
    ],
    weaknesses: [
      'Requires open cranial neurosurgery for bilateral intraputaminal delivery',
      'Ultra-rare disease (~135 cases identified worldwide) limits commercial opportunity',
      'Priced at ~$3.7M (EU); long-term durability beyond 5 years being monitored',
    ],
    source: 'EMA/FDA labels; Chien et al., Sci Transl Med 2017; Kojima et al., Brain 2019; PTC Therapeutics prescribing information',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Dopamine agonist supportive therapy',
    company: 'Standard of care (multiple generic manufacturers)',
    indication: 'Aromatic L-Amino Acid Decarboxylase Deficiency',
    indication_specifics: 'Symptomatic management of AADC deficiency; dopamine agonists, MAO-B inhibitors, and pyridoxine (vitamin B6) supplementation',
    mechanism: 'Dopamine receptor agonists (pramipexole, ropinirole) bypass enzymatic defect to directly stimulate dopamine receptors; MAO-B inhibitors reduce dopamine degradation; pyridoxine (B6) is AADC cofactor',
    mechanism_category: 'supportive_care',
    molecular_target: 'Dopamine D2/D3 receptors (agonists); MAO-B (inhibitors); AADC cofactor (pyridoxine)',
    phase: 'Approved',
    primary_endpoint: 'Symptomatic improvement; oculogyric crisis frequency reduction; motor function',
    key_data: 'Most patients receive combination of pyridoxine (cofactor supplementation), dopamine agonists, and MAO-B inhibitors; response is generally modest and variable; pyridoxine high-dose (100-200 mg/day) may partially enhance residual AADC activity; most patients remain severely affected with minimal voluntary movement despite best medical therapy',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Widely available; can be initiated immediately upon diagnosis',
      'Pyridoxine cofactor therapy may enhance residual AADC enzyme activity',
      'Dopamine agonists provide some symptomatic relief in mild/partial deficiency',
    ],
    weaknesses: [
      'Minimally effective in severe AADC deficiency; most patients remain profoundly disabled',
      'Does not address underlying enzyme deficiency or restore dopamine/serotonin synthesis',
      'Side effects (dyskinesias, nausea, behavioral changes) limit dose escalation',
    ],
    source: 'Wassenberg et al., Orphanet J Rare Dis 2017; Brun et al., JIMD Rep 2010; AADC deficiency consensus guidelines',
    last_updated: '2025-01-15',
  },

];
